Font Size

SCREEN

Profile

Direction

Menu Style

AVG Home

 

AVG Webinar Series

AVG Webinar series

You can listen to the recordings from the AVG webinars which have taken place to date via the links below:

25 October 2022: Treatments/Antiviral Therapeutics - link to the recording

24 January 2023: Antiviral Resistance - link to the recording

20 June 2023: The Present and Future of Treatment Oriented Surveillance - link to the recording

30 Oct 2023: Challenges and Promise of Clinical Trials for Respiratory Antivirals - link to the recording

2024 ISIRV Webinars

24 Jan

If you missed the webinar on 24 Jan on 'RSV Vaccination in the Elderly Population' you can register and watch the recording via this link 

20 March

If you missed this webinar on 'Emerging Influenza and the Human-Animal Interface' you can register and watch the recording via this link 

29 May

If you missed this webinar on ‘Recent antiviral developments for respiratory viral infections’ you can register and watch the recording via this link 

18 June

If you missed this webinar on ‘Bovine Influenza and other Hot Topics in Virus Evolution’ you can register and watch the recording via this link 

 

7th AVG Conference (in-person)

We’ve had some great feedback…. adobe pdf icon2

 
SARS CoV 2
 
SARS-CoV-2 / COVID-19   
Antiviral News

 
AVG Overview

The isirv Antiviral Group (isirv-AVG) was established as a special interest group of isirv at the time of merger in April 2011 of the former Neuraminidase Inhibitor Susceptibility Network (NISN) with isirv. Its specific objectives are to promote understanding of the clinical use of antivirals against respiratory viruses, collate and provide up to date information on the emergence of antiviral resistance, and communicate expert commentary on preclinical and clinical development of potential novel/new antivirals. Read More

 

   isirv Antiviral Group (isirv-AVG) 10th Anniversary

The isirv Antiviral Group was established in 2011 following the merger of the Neuraminidase Inhibitor Susceptibility Network (NISN) with the International Society for Influenza and Other Respiratory Virus Diseases (isirv). Read more

To fulfil its objectives of promoting understanding of the development and clinical use of antivirals against respiratory viruses and the emergence of resistance, the Group has organised a series of AVG conferences on specific topics in different geographical locations plus other smaller specialist meetings and workshops.

The Group gratefully acknowledges the contribution of its partners and the generous financial support from many privateand public organisations that have ensured the success of the Group’s programme of events over the past 10 years.

 


 

Latest…

Multicountry Spread of Influenza A(H1N1)pdm09 Viruses with Reduced Oseltamivir Inhibition, May 2023-February 2024… read more

Comparative Effectiveness of Baloxavir Marboxil and Oseltamivir Treatment in Reducing Household Transmission of Influenza: A Post Hoc Analysis of the BLOCKSTONE Trial… read more

Discovery of baloxavir sodium as a novel anti-CCHFV inhibitor: Biological evaluation of in vitro and in vivo… read more

Ultrapotent influenza hemagglutinin fusion inhibitors developed through SuFEx-enabled high-throughput medicinal chemistry… read more

Spleen tyrosine kinase inhibitor R406 has both antiviral and anti-inflammatory effects on severe influenza A infection… read more
 
 
Antiviral News prepared by: Dr Jeremy C. Jones, Department of Infectious Diseases, St Jude Children’s Research Hospital, Memphis, TN, USA
Visit us on:  facebook  twitter